title: Locally enhanced early bone formation of zoledronic acid incorporated into a bone cement plug in vivo.
abstract: OBJECTIVE
  The aim of the study was to gain experience about the short-term effects of zoledronic acid (ZOL) on bone-implant contact (BIC), bone regeneration and bone area (BA).
  
  
  METHODS
  In this in-vivo study, ZOL was released locally from a drug-loaded pre-shaped calcium phosphate bone cement plug which was implanted into a bone defect in the proximal tibia of rats. At 1 and 3 weeks post implantation, tissue reactions as well as bone regeneration capabilities at the implant site were investigated. Furthermore, tissue samples, harvested at placebo and verum plug sites were used to analyse the gene expression of selected bone-specific markers by using quantitative polymerase chain reaction. Data were normalized against ribosomal RNA (Rn18s) subunits.
  
  
  RESULTS
  In the placebo interface a higher amount of cells could be detected as indicated by higher expression of small subunit Rn18s. Nevertheless, comparing the normalized data of the selected gene expression levels, no significant differences were detected. The histomorphometric results showed a significant higher BIC and BA for ZOL-loaded plugs at 3 weeks after implantation.
  
  
  CONCLUSIONS
  In this model, ZOL was demonstrated to be effective in impacting the bone regeneration process towards reduction of early bone resorption and enhanced bone formation.
authors.affiliation: Department of Pharmaceutics and Biopharmaceutics, Christian-Albrecht-University Kiel, Kiel, Germany.
authors.forename: Torben C
authors.initials: TC
authors.lastname: Sörensen
authors.forename: Jörg
authors.initials: J
authors.lastname: Arnoldi
authors.forename: Philip
authors.initials: P
authors.lastname: Procter
authors.forename: Claudia
authors.initials: C
authors.lastname: Beimel
authors.forename: Anders
authors.initials: A
authors.lastname: Jönsson
authors.forename: Maria
authors.initials: M
authors.lastname: Lennerås
authors.forename: Lena
authors.initials: L
authors.lastname: Emanuelsson
authors.forename: Anders
authors.initials: A
authors.lastname: Palmquist
authors.forename: Peter
authors.initials: P
authors.lastname: Thomsen
authors.forename: Bernd
authors.initials: B
authors.lastname: Robioneck
authors.forename: Hartwig
authors.initials: H
authors.lastname: Steckel
mesh_terms: D000818:Animals; D001843:Bone Cements / Q000737:chemistry*; D001861:Bone Regeneration / Q000187:drug effects* / Q000235:genetics; D002130:Calcium Phosphates / Q000008:administration & dosage*; D004164:Diphosphonates / Q000008:administration & dosage*; D015870:Gene Expression / Q000187:drug effects / Q000235:genetics; D007093:Imidazoles / Q000008:administration & dosage*; D008297:Male; D008855:Microscopy, Electron, Scanning / Q000379:methods; D010012:Osteogenesis / Q000187:drug effects* / Q000235:genetics; D019736:Prostheses and Implants; D051381:Rats; D017207:Rats, Sprague-Dawley; D013977:Tibia / Q000187:drug effects / Q000378:metabolism; D000077211:Zoledronic Acid
chemical_list: D001843:Bone Cements; D002130:Calcium Phosphates; D004164:Diphosphonates; D007093:Imidazoles; D000077211:Zoledronic Acid